Tourette Syndrome - Pipeline Review, H1 2018

Publication ID:
GMD0118009

Publication Date:
January 18, 2018

Pages:
82

Publisher:
Global Markets Direct

Region:
Global [1]

$2,000.00

Publication License Type *
○ Single User License (PDF), $2,000.00
○ Site License (PDF), $4,000.00
○ Global License (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart

Description:
Tourette Syndrome - Pipeline Review, H1 2018
Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Pipeline Review, H1 2018, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 6, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

**Table Of Contents:**

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tourette Syndrome - Dormant Projects
Tourette Syndrome - Discontinued Products
Tourette Syndrome - Product Development Milestones
Featured News & Press Releases
Jan 03, 2018: Zyneba Pharmaceuticals Provides Update on fibromyalgia Drug Candidate ZYN-001
Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
Nov 28, 2017: Abide Therapeutics Reports Positive Topline Data from Phase 1b Study of ABX-1431 in Tourette Syndrome
Oct 25, 2017: Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA in Children and Adolescents with Tourette Syndrome
Oct 23, 2017: Neurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette Syndrome
Oct 11, 2017: Nippon Chemipharm and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)
May 23, 2017: Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA For Treatment of Tourette Syndrome
May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome
Apr 18, 2017: Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America
Jan 17, 2017: Psyadon Announces Positive Results from Phase 2b Clinical Study of Ecopipam for the Treatment of Tourette's Syndrome in Children
Jan 17, 2017: Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA (valbenazine) in Adults with Tourette Syndrome
Jan 04, 2017: Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Yale University for Treating Tourette's Syndrome Using Cannabinoid-based Drug
Aug 31, 2016: Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA for VMAT2 Inhibitor Valbenazine
Jul 28, 2016: Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
Jun 15, 2016: Therapix Biosciences Filed an Application with the FDA to Approve an Orphan Designation for the Drug Developed Based on the Entourage Technology for Treating Tourettes Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
List of Tables

- Number of Products under Development for Tourette Syndrome, H1 2018
- Number of Products under Development by Companies, H1 2018
- Number of Products under Development by Universities/Institutes, H1 2018
- Products under Development by Companies, H1 2018
- Products under Development by Universities/Institutes, H1 2018
- Number of Products by Stage and Target, H1 2018
- Number of Products by Stage and Mechanism of Action, H1 2018
- Number of Products by Stage and Route of Administration, H1 2018
- Number of Products by Stage and Molecule Type, H1 2018
- Tourette Syndrome - Pipeline by Abide Therapeutics Inc, H1 2018
- Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals Inc, H1 2018
- Tourette Syndrome - Pipeline by Neurocrine Biosciences Inc, H1 2018
- Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals Inc, H1 2018
- Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc, H1 2018
- Tourette Syndrome - Pipeline by SOM Biotech SL, H1 2018
- Tourette Syndrome - Pipeline by Synchroneuron Inc, H1 2018
- Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
- Tourette Syndrome - Pipeline by Therapix Biosciences Ltd, H1 2018
- Tourette Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, H1 2018
- Tourette Syndrome - Dormant Projects, H1 2018
- Tourette Syndrome - Discontinued Products, H1 2018

List of Figures

- Number of Products under Development for Tourette Syndrome, H1 2018
- Number of Products under Development by Companies, H1 2018
- Number of Products by Top 10 Targets, H1 2018
- Number of Products by Stage and Top 10 Targets, H1 2018
- Number of Products by Top 10 Mechanism of Actions, H1 2018
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
- Number of Products by Routes of Administration, H1 2018
- Number of Products by Stage and Routes of Administration, H1 2018
- Number of Products by Stage and Molecule Types, H1 2018

Companies Mentioned:

- Abide Therapeutics Inc
License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.
Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.
What is drug pipeline research?  
March 20

How to use market research to bring your idea to life?  
March 11

How to gain business insights using syndicated market research?  
March 10

Source URL: https://www.drugpipeline.net/global-markets-direct/tourette-syndrome-pipeline-review-h1-2018

Links
[1] https://www.drugpipeline.net/region/global